HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
Our centers are performing as expected or even better
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Subscribe To Our Newsletter & Stay Updated